Sumitomo Pharma Co Ltd 2019 IR
The report outlines Sumitomo Dainippon Pharma's business performance and strategic initiatives for the fiscal year ended March 31, 2019, under its Mid-term Business Plan 2022. The company highlights its transition to a 'Global Specialized Player' by 2033, focusing on psychiatry and neurology, oncology, and regenerative medicine/cell therapy. Key achievements include the resolution of the LATUDA ANDA lawsuits in North America and progress in clinical trials for SEP-363856. The report also details the company's commitment to ESG initiatives, including work style innovation, diversity and inclusion, and environmental conservation targets.
Company: Sumitomo Pharma Co Ltd
Sector: Health Care
Country: Japan
Year: 2019
Type: IR
Pages: 130
Sumitomo Pharma Co Ltd
Integrated Report
The report outlines Sumitomo Dainippon Pharma's business performance and strategic initiatives for the fiscal year ended March 31, 2019, under its Mid-term Business Plan 2022. The company highlights its transition to a 'Global Specialized Player' by 2033, focusing on psychiatry and neurology, oncology, and regenerative medicine/cell therapy. Key achievements include the resolution of the LATUDA ANDA lawsuits in North America and progress in clinical trials for SEP-363856. The report also details the company's commitment to ESG initiatives, including work style innovation, diversity and inclusion, and environmental conservation targets.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2019
Reporting Period
Apr 1, 2018 - Mar 31, 2019
Fiscal Year
2018
Type
Integrated Report
Language
English
Pages
File Size
Standards & Assurance
Materiality Assessment
Assurance
Assurance Provider
Assurance Standard
ESG Data?Experimental — AI-extracted data, may contain inaccuracies
Emissions
Scope 1:
Scope 2:
Scope 3:
Energy Consumption
Total Waste
Women in Management
Employees